Clinical Trial Update: A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of the Phase 2 PROVE3 study evaluating telaprevir in combination with peginterferon alfa-2a (Pegasys) and riba…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• Telaprevir (VX-950) (telaprevir)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2011-07-21